newsfilter
← Earnings
Earnings Releases·

Retension Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $5.9 million for Q3 2026, widening from $1.5 million in the prior year period, driven by a $3.6 million increase in R&D expenses and higher G&A costs.
  • Completed an upsized IPO in October 2026 generating $45.1 million in net proceeds, bringing pro forma cash and cash equivalents to approximately $54.3 million as of September 30, 2026.
  • Phase 2b clinical trial data for lead candidate RTN-001 is expected in the first half of 2027 to inform dose selection for an upcoming Phase 3 trial.
  • Strengthened executive leadership and formed a Scientific Advisory Board to support the advancement of RTN-001 for uncontrolled and resistant hypertension.
Company
RETENSION PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology